质子泵抑制剂治疗的并发症
本文综述质子泵抑制剂(PPI)多种拟议不良反应,并采用既定因果判定标准评估证据。作者认为证据不足以确立许多关联的因果关系,残余混杂与对微小效应量的过度外推可能导致了当前争议;有明确指征者应以最低有效剂量继续PPI治疗,不推荐对初始经验治疗无反应者升级剂量或长期维持。
要点
- 证据不足以确立PPI治疗与许多拟议关联之间的因果关系。
- 研究设计相关的残余混杂和对微小效应量的过度外推可能导致了当前PPI安全性的争议。
- 有明确PPI指征的患者应以最低有效剂量继续治疗。
核心结论
- 证据不足以确立PPI治疗与许多拟议关联之间的因果关系。
- 研究设计相关的残余混杂和对微小效应量的过度外推可能导致了当前关于PPI安全性的争议。
- 有明确PPI指征的患者应以最低有效剂量继续接受PPI治疗。
- 不推荐对初始经验性治疗无反应者进行PPI剂量升级和持续长期治疗。
研究设计与样本
- 本文为综述,评估PPI治疗拟议不良反应的证据并应用既定因果判定标准。
主要发现
- 证据不足以确立PPI治疗与许多拟议关联之间的因果关系。
- 研究设计相关的残余混杂和对微小效应量的过度外推可能导致了当前关于PPI安全性的争议,进而引起患者和处方者的不必要担忧。
关键数值与推荐
- 有明确PPI指征的患者应以最低有效剂量继续接受PPI治疗。
- 不推荐对初始经验性治疗无反应者进行PPI剂量升级和持续长期治疗。
临床怎么用
- 有明确PPI指征的患者应以最低有效剂量继续接受PPI治疗。
- 不推荐对初始经验性治疗无反应者进行PPI剂量升级和持续长期治疗。
局限性
- 许多已报告的研究中存在残余混杂。
- 研究设计相关的残余混杂和对微小效应量的过度外推可能导致了当前关于PPI安全性的争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Safety issues associated with proton pump inhibitors (PPIs) have recently attracted widespread media and lay attention. Gastroenterologists are frequently asked about the appropriateness of PPI therapy for specific patients. Furthermore, some patients may have had PPI therapy discontinued abruptly or inappropriately due to safety concerns. Faced with such a wide variety of potentially serious adverse consequences, prescribers need to evaluate the evidence objectively to discern the likelihood that any reported association might actually be causal. Here, we review many of the proposed adverse consequences of PPI therapy and apply established criteria for the determination of causation. We also consider the potential contribution of residual confounding in many of the reported studies. Evidence is inadequate to establish causal relationships between PPI therapy and many of the proposed associations. Residual confounding related to study design and the overextrapolation of quantitatively small estimates of effect size have probably led to much of the current controversy about PPI safety. In turn, this has caused unnecessary concern among patients and prescribers. The benefits of PPI therapy for appropriate indications need to be considered, along with the likelihood of the proposed risks. Patients with a proven indication for a PPI should continue to receive it in the lowest effective dose. PPI dose escalation and continued chronic therapy in those unresponsive to initial empiric therapy is discouraged.
引用
- Vaezi MF, Yang YX, Howden CW, et al. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017. PMID: 28528705. doi:10.1053/j.gastro.2017.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。